Febuxostat is a non purine selective xanthine oxidase inhibitor that inhibits the oxidative and reductive activities of xanthine oxidase (Ki values of 0.6 nmol/L and 3.1 nmol/L, respectively), blocking the key step of uric acid production and reducing blood uric acid levels.

1、 Drug name

Common name: Febuxostat

English name: Febuxostat ODTablets

2、 Indications

Gout and hyperuricemia.

Hyperuricemia associated with tumor chemotherapy.

3、 Specifications and characteristics

80mg、 Tablets.

4、 Main components

Active ingredient: Febuxostat.

5、 Usage and dosage

Gout and hyperuricemia:

The usual starting dose for adults is 10mg/day, taken orally once daily.

According to the gradual increase in blood uric acid levels, the maintenance dose is usually 40mg/day, with a maximum dose of 60mg/day.

Chemotherapy related hyperuricemia:

The usual dosage for adults is 60mg/day, taken orally once daily.

It is recommended to start administering the medication 1-2 days before chemotherapy and continue until the 5th day after the start of chemotherapy, and may be extended if necessary.

6、 Dose adjustment

At the beginning of treatment, the dosage should be slowly increased to reduce the risk of gout attacks.

Adjust the dosage based on blood uric acid monitoring results and patient tolerance.

Patients with renal or liver dysfunction should be carefully adjusted and follow medical advice.

7、 Medication precautions

Medication method:

It can be orally administered (disintegrating after saliva infiltration) or taken with water.

Do not take medication without water while lying in bed.

Missing server:

If missed, it should be replenished as soon as possible; If it is close to the next medication time, skip this time and take the medication according to the original plan.

vomit:

If vomiting occurs after taking medication, it is not recommended to take it again and wait for the next normal medication time.

Others:

Take it out of the PTP packaging and avoid swallowing the packaging tablets by mistake.

Gout attacks may occur in the early stages of treatment, and it is recommended to use colchicine or NSAIDs for prevention.

8、 Medication for special populations

Pregnant women: Use only when the benefits outweigh the risks.

Breastfeeding women should weigh the benefits of treatment and breastfeeding before deciding whether to continue breastfeeding.

Children: Safety and efficacy have not been established.

Elderly people: Physical function may decline, medication should be taken with caution.

Patients with liver and kidney dysfunction: need to be closely monitored, and the dosage should be adjusted according to individual needs.

9、 Adverse reactions

Common adverse reactions (≥ 1%): abnormal liver function, joint pain, rash, diarrhea, nausea, etc.

Serious adverse reactions:

Liver function impairment.

Allergic reactions.

Cardiovascular event risk (such as cardiovascular death).

Other: abnormalities in the blood system, endocrine disorders, neurological symptoms, etc.

10、 Contraindications

People who are allergic to the ingredients of this medicine.

Patients who are currently using mercaptopurine or azathioprine.

11、 Drug interactions

Prohibited combination: mercaptopurine, azathioprine (may enhance bone marrow suppression).

Use with caution:

Didanoxin and Bidalabin (may increase toxicity).

Rosuvastatin (may increase blood drug concentration).

Colchicine, nonsteroidal anti-inflammatory drugs, warfarin, diuretics, etc. (corresponding indicators need to be monitored).

12、 Storage method

Store at room temperature and avoid moisture.

Aluminum plastic packaging should be stored against moisture after opening.

Validity period: 3 years.

Febuxostatinformation